Ehrlichiosis is an emerging tick-borne infection caused by obligate intracellular bacteria — primarily Ehrlichia chaffeensis (human monocytic ehrlichiosis, HME), E. ewingii, and E. muris eauclairensis — transmitted by the lone star tick (Amblyomma americanum) and blacklegged tick (Ixodes scapularis). [1-2] It is a nationally notifiable disease concentrated in the southeastern and south-central United States, peaking May–August. [2-3] The overall case fatality rate is approximately 11.6%, higher in immunocompromised patients (16.3% vs 9.9%). [4]
1. History
- Tick exposure: Ask about outdoor activities (hiking, camping, fishing, gardening, hunting), occupational exposure (forestry, farming, landscaping), and pet tick exposure within the prior 1–3 weeks [3]
- Timing: Incubation period 5–14 days (median 9 days) after tick bite [1][3]
- Symptom characterization: Acute onset of high fever, chills, severe headache, malaise, myalgias [2-3]
- GI symptoms: Nausea (57%), vomiting (47%), diarrhea (25%), abdominal pain — more prominent in children [3]
- Rash: Present in ~30% of patients; more common in children; maculopapular or petechial, appearing ~5 days after illness onset [3]
- Respiratory: Cough in ~28%, more common in adults [3]
- Neurologic: Confusion, altered mental status (~20% develop meningitis/meningoencephalitis) [3][5]
- Important negatives: Ask about erythema migrans (Lyme), eschar (RMSF/Rickettsia parkeri), conjunctival suffusion (leptospirosis)
2. Alarm Features
- Altered mental status / meningoencephalitis [3][5]
- Toxic shock-like or septic shock-like syndrome [3]
- ARDS or progressive respiratory failure [4][6]
- Acute renal failure [4]
- DIC / hemorrhagic manifestations [3]
- Hemophagocytic lymphohistiocytosis (HLH): Occurs in up to 16% of cases; suspect with refractory cytopenias, hyperferritinemia, hepatosplenomegaly [4][7]
- Multi-organ failure — higher incidence in immunocompromised (26% vs 14.9%) [4]
- Failure to defervesce within 48 hours of doxycycline should prompt reconsideration of diagnosis or evaluation for coinfection [3]
3. Medications
- First-line (all ages): Doxycycline 100 mg PO/IV BID (adults); 2.2 mg/kg PO/IV BID (children <45 kg) [1-2]
- Treat for at least 3 days after fever subsides, minimum 5–7 days total [1][3]
- Safe in children <8 years — no evidence of dental staining at recommended doses [2]
- Alternative (limited): Rifampin 300 mg PO BID (adults) or 10 mg/kg (children) — only for mild illness with true doxycycline allergy; no clinical trial data [3]
- Contraindicated / Ineffective:
- Chloramphenicol — in vitro resistance; NOT effective for ehrlichiosis [3][8]
- Sulfonamides (TMP-SMX) — associated with increased disease severity [3]
- Beta-lactams, macrolides, aminoglycosides, fluoroquinolones — all ineffective [3][8]
- Pearl: Using antibiotics other than doxycycline increases the risk of death per CDC [2]
- Pregnancy: Consult infectious disease; rifampin may be considered [3][9]
4. Diet
- No specific dietary triggers or restrictions
- Hydration is critical, especially with GI losses (vomiting, diarrhea)
- Ensure adequate oral intake; IV fluids if unable to tolerate PO
5. Review of Systems
- Constitutional: Fever, chills, rigors, malaise, fatigue, anorexia
- MSK: Myalgias, arthralgias
- GI: Nausea, vomiting, diarrhea, abdominal pain
- Neuro: Headache, confusion, neck stiffness, seizures, focal deficits [5]
- Respiratory: Cough, dyspnea
- Skin: Rash (trunk, extremities; may involve palms/soles) [3]
- Heme: Easy bruising, petechiae (thrombocytopenia-related)
6. Collateral History and Family History
- Collateral: Confirm tick exposure, geographic travel, outdoor activities, timeline of symptom onset relative to exposure [3]
- Immunosuppression status: Organ transplant, HIV, chemotherapy, chronic steroids — immunocompromised patients are overrepresented (26.7% of reported cases) and have worse outcomes [4][7]
- Family history: No hereditary predisposition, but household members with similar exposures may also be at risk
- Pet history: Dogs with attached ticks indicate peridomestic tick infestation [3]
7. Risk Factors
- Geographic: Southeastern and south-central US (MO, AR, NC, NY account for ~50% of cases); E. muris eauclairensis in Upper Midwest (MN, WI) [2]
- Seasonal: Peak May–August [3]
- Outdoor exposure: Camping, hiking, fishing, hunting, gardening, military exercises [3]
- Immunosuppression: Transplant recipients, HIV, malignancy — higher complication and mortality rates [4][7]
- Age: Older adults at higher risk for severe disease [5]
- Delayed treatment: Strongly associated with adverse outcomes [2][10]
8. Differential Diagnosis
- Rocky Mountain Spotted Fever (RMSF): Rash more common (petechial, centripetal spread to palms/soles); higher mortality if untreated; same empiric treatment (doxycycline) [11-12]
- Anaplasmosis: Similar presentation; northeastern/upper Midwest distribution; rash uncommon [1][13]
- Lyme disease: Erythema migrans rash; articular/neurologic/cardiac manifestations [13]
- Babesiosis: Hemolytic anemia, parasitemia on smear; asplenic patients at high risk [13]
- Heartland virus disease: Transmitted by same lone star tick; closely mimics ehrlichiosis [3]
- Sepsis / meningococcemia / endocarditis: Consider in undifferentiated febrile illness with cytopenias [12]
- Hematologic malignancy / TTP / HLH: Cytopenias and organomegaly may mimic [3][12]
- Other: Tularemia, Q fever, leptospirosis, murine typhus, West Nile fever [12]
Key distinguishing feature: The triad of fever + leukopenia + thrombocytopenia + elevated transaminases in a tick-endemic area during tick season is highly suggestive of ehrlichiosis [2][10]
9. Past Medical History
- Immunosuppression: Transplant, HIV/AIDS, active malignancy, chronic immunosuppressive therapy — significantly increases risk of severe disease and complications [4]
- Prior tick-borne illness: Previous episodes do not confer lasting immunity
- Splenectomy: Increases risk for severe tick-borne infections generally
- Chronic liver/kidney disease: May complicate management and increase organ failure risk
10. Physical Exam
- Vitals: Fever (often >38.5°C), tachycardia; hypotension in severe/shock-like cases
- Skin: Maculopapular or petechial rash on trunk/extremities (may involve palms, soles, face); look for tick attachment site; note that rash is absent in ~70% of adults [3]
- HEENT: Pharyngeal erythema (occasionally); no conjunctival suffusion (unlike leptospirosis)
- Lymph nodes: Lymphadenopathy may be present
- Abdomen: Hepatosplenomegaly possible; diffuse tenderness
- Neuro: Mental status changes, meningismus, focal deficits (in neuro-ehrlichiosis) [5]
- Respiratory: Crackles if ARDS developing
- Skin color consideration: Rash may be difficult to recognize in patients with darker skin tones [14]
11. Lab Studies
- CBC: Leukopenia (57.8%), thrombocytopenia (79.1%), anemia (later in course) [2][4]
- CMP: Elevated hepatic transaminases (68.1% of cases); elevated creatinine in renal involvement [2][4]
- LDH: Often elevated
- Coagulation studies: PT/INR, fibrinogen, D-dimer if DIC suspected
- Ferritin, triglycerides, soluble IL-2 receptor: If HLH suspected [6-7]
- Blood smear: Morulae visible in monocytes (E. chaffeensis) or granulocytes (E. ewingii) in ~20% of patients — highly suggestive but insensitive [2]
- Rule-out labs: Blood cultures (sepsis), thick/thin smear (babesiosis/malaria), Lyme serologies if coinfection suspected
12. Imaging
- Chest X-ray: If respiratory symptoms present; may show infiltrates or ARDS pattern
- CT head: If altered mental status or focal neurologic deficits — typically unremarkable in neuro-ehrlichiosis [5]
- Abdominal imaging: Generally not indicated unless evaluating for hepatosplenomegaly or alternative diagnoses
- Imaging is not diagnostic for ehrlichiosis and is used primarily to evaluate complications or exclude alternative diagnoses
13. Special Tests
- PCR (NAAT) of whole blood: Primary diagnostic test for acute infection (<10 days); sensitivity >95% [9][14]
- Most sensitive during the first week of illness; sensitivity decreases after doxycycline administration [2]
- Send in EDTA or heparin tube, transport on ice within 1 hour [14]
- Serology (IFA for IgG): For patients presenting >10 days post-symptom onset; requires paired sera (acute + convalescent 2–4 weeks later) with ≥4-fold rise in titer [2][14]
- Antibody titers frequently negative in first 7–10 days — do not rely on acute serology alone [2]
- IgM is less specific and should not be used alone [2]
- Elevated IgG titer ≥1:128 may support diagnosis in later presentations [14]
- Peripheral blood smear: Wright or Giemsa stain for morulae — sensitivity only 20–75% vs >95% for NAAT [2][14]
- Lumbar puncture: If meningoencephalitis suspected; CSF may show lymphocytic pleocytosis
- Bone marrow biopsy: If HLH suspected; may show hemophagocytosis [6]
14. ECG
- Ehrlichiosis is not typically associated with primary cardiac pathology; unlike RMSF, direct vasculitis and endothelial injury are rare [3]
- Myocarditis/pericarditis is an uncommon complication, more associated with anaplasmosis than E. chaffeensis [15]
- ECG indicated if: chest pain, hemodynamic instability, or concern for myocarditis
- Monitor for sinus tachycardia (fever, sepsis) and arrhythmias in critically ill patients
15. Assessment
Typical presentation: Acute febrile illness 5–14 days after tick exposure in an endemic area, with headache, myalgias, and GI symptoms, accompanied by the laboratory triad of leukopenia, thrombocytopenia, and elevated transaminases. [4][10]
Severity stratification
- Mild: Fever, myalgias, mild cytopenias; tolerating PO
- Moderate: Significant cytopenias, transaminitis, GI symptoms limiting PO intake
- Severe: AMS, ARDS, renal failure, DIC, HLH, shock — case fatality up to 16.3% in immunocompromised [4]
Atypical presentations: May mimic appendicitis, fulminant viral hepatitis, TTP, or systemic vasculitis. [3][12] Neuro-ehrlichiosis can present with seizures, amnesia, or focal deficits mimicking stroke, often with unremarkable neuroimaging. [5]
16. Treatment Plan
Initial stabilization
- ABCs; IV access, fluid resuscitation if hemodynamically unstable
- Start doxycycline immediately on clinical suspicion — do NOT wait for confirmatory testing [2-3]
Antibiotic therapy
- Adults: Doxycycline 100 mg PO/IV BID
- Children: Doxycycline 2.2 mg/kg PO/IV BID (max 100 mg/dose)
- Duration: At least 3 days after defervescence, minimum 5–7 days total [1][3]
- IV route for patients who are vomiting, obtunded, or critically ill [3]
Supportive care
- IV fluids, antiemetics, antipyretics
- Blood product transfusion for severe thrombocytopenia or anemia
- Mechanical ventilation for ARDS; RRT for renal failure
- HLH protocol (dexamethasone/etoposide) if secondary HLH confirmed [6]
Expected response: Fever typically resolves within 24–48 hours of doxycycline initiation if started within the first 4–5 days of illness. [3]
17. Disposition
Admission criteria: [3]
- Organ dysfunction (renal, hepatic, respiratory)
- Severe thrombocytopenia or coagulopathy
- Altered mental status / meningoencephalitis
- Inability to tolerate oral medications
- Hemodynamic instability
- Immunocompromised host with moderate-severe disease
- Concern for HLH (median hospital stay 9 days for HLH vs 4 days without) [7]
Discharge criteria
- Mild disease, tolerating PO doxycycline
- Stable vitals, improving labs
- Reliable follow-up and ability to return if worsening
Specialist consultation
- Infectious disease: Pregnancy, doxycycline allergy, severe/complicated disease, HLH
- Hematology: If HLH suspected
- Critical care: ARDS, shock, multi-organ failure
18. Follow Up / Return Precautions
- Follow-up: Within 48–72 hours of ED discharge to reassess clinical response and repeat labs (CBC, LFTs)
- Expected course: Defervescence within 24–48 hours of doxycycline; if no improvement by 48 hours, reconsider diagnosis or evaluate for coinfection [3]
- Return immediately for: Worsening fever, confusion or altered mental status, new rash, shortness of breath, bleeding, inability to keep medications down
- Convalescent serology: Paired sera 2–4 weeks after acute sample for confirmatory diagnosis [2]
- Reporting: Ehrlichiosis is a nationally notifiable disease — report to local/state health department [9]
- Tick prevention counseling: DEET or permethrin-treated clothing, daily tick checks, prompt tick removal, avoidance of high-risk habitats during peak season [3]
Images
References
1. Wilderness Medical Society Clinical Practice Guidelines for the Prevention and Management of Tick-Borne Illness in the United States. — Ho BM, Davis HE, Forrester JD, et al. Wilderness & Environmental Medicine. 2021.
2. Tickborne Diseases of the United States: A Reference Manual for Healthcare Providers Sixth Edition. — Nancy Shadick MD MPH, Nancy Maher MPH, Dennis Hoak MD United States Centers for Disease Control and Prevention (2022). 2022.
3. Diagnosis and Management of Tickborne Rickettsial Diseases: Rocky Mountain Spotted Fever and Other Spotted Fever Group Rickettsioses, Ehrlichioses, and Anaplasmosis - United States. — Biggs HM, Behravesh CB, Bradley KK, et al. MMWR. Recommendations and Reports : Morbidity and Mortality Weekly Report. Recommendations and Reports. 2016.
4. Human Monocytotropic Ehrlichiosis-a Systematic Review and Analysis of the Literature. — Gygax L, Schudel S, Kositz C, Kuenzli E, Neumayr A. PLoS Neglected Tropical Diseases. 2024.
5. Neurological Manifestations of Ehrlichiosis Among a Cohort of Patients: Prevalence and Clinical Symptoms. — Iyamu O, Ciccone EJ, Schulz A, et al. BMC Infectious Diseases. 2024.
6. Use of Extracorporeal Support in Hemophagocytic Lymphohistiocytosis Secondary to Ehrlichiosis. — Cheng A, Williams F, Fortenberry J, et al. Pediatrics. 2016.
7. Human Ehrlichiosis at a Tertiary-Care Academic Medical Center: Clinical Associations and Outcomes of Transplant Patients and Patients With Hemophagocytic Lymphohistiocytosis. — Otrock ZK, Eby CS, Burnham CD. Blood Cells, Molecules & Diseases. 2019.
8. In Vitro Antibiotic Susceptibility of the Newly Recognized Agent of Ehrlichiosis in Humans, Ehrlichia Chaffeensis. — Brouqui P, Raoult D. Antimicrobial Agents and Chemotherapy. 1992.
9. Rickettsial Diseases. — David W. McCormick and William L. Nicholson CDC Yellow Book. 2025.
10. Ehrlichioses in Humans: Epidemiology, Clinical Presentation, Diagnosis, and Treatment. — Dumler JS, Madigan JE, Pusterla N, Bakken JS. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2007.
11. "Leopards Do Not Change Their Spots:" Tick Borne Disease Symptomology Case Report. — Abernathy H, Alejo A, Arahirwa V, et al. BMC Infectious Diseases. 2022.
12. Human Monocytic Ehrlichiosis. — Stone JH, Dierberg K, Aram G, Dumler JS. The Journal of the American Medical Association. 2004.
13. Fever of Unknown Origin. — Haidar G, Singh N. The New England Journal of Medicine. 2022.
14. Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2024 Update by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM). — Miller JM, Binnicker MJ, Campbell S, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2024.
15. Rickettsial, Ehrlichial and Bartonella Infections of the Myocardium and Pericardium. — Shah SS, McGowan JP. Frontiers in Bioscience : A Journal and Virtual Library. 2003.